Tech Transfer Tidbits

Premium

Germany's Merck Serono Launches Venture Fund for Early-Stage Biotechs

Merck Serono, a division of Germany's Merck, said this week that it has formed Merck Serono Ventures to invest in emerging biotechnology companies.

The fund, which has an initial commitment to invest up to €40 million ($54.2 million) over the next five years, will support biotech startup companies that have the potential to provide innovative products in Merck Serono's core therapeutic areas, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.